Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation (Q37559627)

21 August 2017

1 reference

title

Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation (English)

1 reference

stem cell transplantation

21 August 2017

0 references

1 reference

Wolfgang Herr

1

1 reference

21 August 2017

Bodo Plachter

series ordinal

2

1 reference

21 August 2017

publication date

1 August 2009

1 reference

Expert Review of Vaccines

21 August 2017

published in

1 reference

21 August 2017

volume

8

1 reference

21 August 2017

issue

8

1 reference

21 August 2017

page(s)

999-1021

1 reference

Genetic content of wild-type human cytomegalovirus

21 August 2017

cites work

1 reference

Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells

21 January 2018

1 reference

Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells

21 January 2018

1 reference

Cytomegalovirus infection

21 January 2018

1 reference

Congenital cytomegalovirus infections

21 January 2018

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease

21 January 2018

1 reference

Prevention and management of cytomegalovirus infection in solid-organ transplantation

21 January 2018

1 reference

The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'.

21 January 2018

1 reference

Delayed-onset primary cytomegalovirus disease after liver transplantation

21 January 2018

1 reference

Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation

21 January 2018

1 reference

Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy

21 January 2018

1 reference

Clinical aspects of CMV infection after stem cell transplantation

21 January 2018

1 reference

Risk assessment in haematopoietic stem cell transplantation: viral status

21 January 2018

1 reference

CMV infections after hematopoietic stem cell transplantation

21 January 2018

1 reference

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

21 January 2018

1 reference

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

21 January 2018

1 reference

21 January 2018

1 reference

How we treat cytomegalovirus in hematopoietic cell transplant recipients

21 January 2018

1 reference

Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus

21 January 2018

1 reference

Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection

21 January 2018

1 reference

Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus.

21 January 2018

1 reference

Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice

21 January 2018

1 reference

Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection

21 January 2018

1 reference

Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine

21 January 2018

1 reference

Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response

21 January 2018

1 reference

Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response

21 January 2018

1 reference

Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface

21 January 2018

1 reference

Entry route of HCMV into endothelial cells

21 January 2018

1 reference

Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes

21 January 2018

1 reference

Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells.

21 January 2018

1 reference

Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism

21 January 2018

1 reference

Role of human cytomegalovirus UL131A in cell type-specific virus entry and release

21 January 2018

1 reference

Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion

21 January 2018

1 reference

Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism

21 January 2018

1 reference

Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells.

21 January 2018

1 reference

HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors

21 January 2018

1 reference

Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection

21 January 2018

1 reference

Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection.

21 January 2018

1 reference

CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation

21 January 2018

1 reference

Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.

21 January 2018

1 reference

Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation

21 January 2018

1 reference

Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation

21 January 2018

1 reference

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

21 January 2018

1 reference

Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H.

21 January 2018

1 reference

Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response

21 January 2018

1 reference

Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals

21 January 2018

1 reference

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

21 January 2018

1 reference

Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation

21 January 2018

1 reference

Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses

21 January 2018

1 reference

Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells

21 January 2018

1 reference

Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells

21 January 2018

1 reference

Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients

21 January 2018

1 reference

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers

21 January 2018

1 reference

Progress toward an elusive goal: current status of cytomegalovirus vaccines

21 January 2018

1 reference

Human cytomegalovirus vaccine: time to look for alternative options.

21 January 2018

1 reference

Vaccine strategies against human cytomegalovirus infection.

21 January 2018

1 reference

Immunobiology of human cytomegalovirus: from bench to bedside.

21 January 2018

1 reference

Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.

21 January 2018

1 reference

Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection

21 January 2018

1 reference

Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10

21 January 2018

1 reference

Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR alpha-chain.

21 January 2018

1 reference

Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system

21 January 2018

1 reference

Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination

21 January 2018

1 reference

CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model

21 January 2018

1 reference

Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

Monitoring human cytomegalovirus infection in transplant recipients

21 January 2018

1 reference

Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation

21 January 2018

1 reference

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

21 January 2018

1 reference

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis

21 January 2018

1 reference

Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR.

21 January 2018

1 reference

Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia

21 January 2018

1 reference

Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants.

21 January 2018

1 reference

Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

21 January 2018

1 reference

Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients

21 January 2018

1 reference

Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT.

21 January 2018

1 reference

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

21 January 2018

1 reference

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

21 January 2018

1 reference

Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting

21 January 2018

1 reference

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

21 January 2018

1 reference

Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants

21 January 2018

1 reference

Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution.

21 January 2018

1 reference

Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.

21 January 2018

1 reference

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.

21 January 2018

1 reference

Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention

21 January 2018

1 reference

Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.

21 January 2018

1 reference

A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.

21 January 2018

1 reference

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

21 January 2018

1 reference

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

21 January 2018

1 reference

Vaccine prevention of maternal cytomegalovirus infection

21 January 2018

1 reference

Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes

21 January 2018

1 reference

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus

21 January 2018

1 reference

Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins

21 January 2018

1 reference

Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection

21 January 2018

1 reference

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

21 January 2018

1 reference

Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells.

21 January 2018

1 reference

Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

21 January 2018

1 reference

A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector.

21 January 2018

1 reference

Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques

21 January 2018

1 reference

DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice

21 January 2018

1 reference

Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques

21 January 2018

1 reference

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

21 January 2018

1 reference

A cytomegalovirus vaccine for transplantation: are we closer?

21 January 2018

1 reference

A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus

21 January 2018

1 reference

Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells.

21 January 2018

1 reference

Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.

21 January 2018

1 reference

Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy.

21 January 2018

1 reference

Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus

21 January 2018

1 reference

Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome

21 January 2018

1 reference

Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression

21 January 2018

1 reference

Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies.

21 January 2018

1 reference

Refinement of strategies for the development of a human cytomegalovirus dense body vaccine

21 January 2018

1 reference

Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles

21 January 2018

1 reference

Vaccination after stem cell transplant: a review of recent developments and implications for current practice

21 January 2018

1 reference

Human clinical trials of plasmid DNA vaccines

21 January 2018

1 reference

Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication

21 January 2018

1 reference

Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge

21 January 2018

1 reference

DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge.

21 January 2018

1 reference

Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults

21 January 2018

1 reference

Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.

21 January 2018

1 reference

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

21 January 2018

1 reference

Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses

21 January 2018

1 reference

Protein delivery by subviral particles of human cytomegalovirus

21 January 2018

1 reference

Sustained expression of human cytomegalovirus glycoprotein B (UL55) in the seeds of homozygous rice plants.

21 January 2018

1 reference

Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy.

21 January 2018

1 reference

Exploiting the yeast L-A viral capsid for the in vivo assembly of chimeric VLPs as platform in vaccine development and foreign protein expression

21 January 2018

1 reference

Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo.

21 January 2018

1 reference

Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine

21 January 2018

1 reference

The complete DNA sequence of varicella-zoster virus

21 January 2018

1 reference

Zoster in patients infected with HIV: a review

21 January 2018

1 reference

Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir

21 January 2018

1 reference

Varicella-Zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients

21 January 2018

1 reference

Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation

21 January 2018

1 reference

Humoral and cellular immunity to varicella-zoster virus: an overview

21 January 2018

1 reference

Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha

21 January 2018

1 reference

Varicella-zoster virus immune evasion

21 January 2018

1 reference

Modulation of major histocompatibility class II protein expression by varicella-zoster virus

21 January 2018

1 reference

Immune evasion as a pathogenic mechanism of varicella zoster virus

21 January 2018

1 reference

Downregulation of class I major histocompatibility complex surface expression by varicella-zoster virus involves open reading frame 66 protein kinase-dependent and -independent mechanisms.

21 January 2018

1 reference

Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome.

21 January 2018

1 reference

Infection with varicella-zoster virus after marrow transplantation

21 January 2018

1 reference

Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine

21 January 2018

1 reference

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

21 January 2018

1 reference

Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

21 January 2018

1 reference

The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation

21 January 2018

1 reference

Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study

21 January 2018

1 reference

One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation

21 January 2018

1 reference

Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster

21 January 2018

1 reference

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

Varicella-zoster reactivation in a patient receiving routine revaccinations after an allogeneic hemopoietic progenitors transplant

21 January 2018

1 reference

Susceptibility of Oka varicella vaccine strain to antiviral drugs.

21 January 2018

1 reference

Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination

21 January 2018

1 reference

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine

21 January 2018

1 reference

Human cytomegalovirus DNA replication: antiviral targets and drugs

21 January 2018

1 reference

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

21 January 2018

1 reference

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens

21 January 2018

1 reference

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

21 January 2018

1 reference

Development of a cytomegalovirus vaccine: lessons from recent clinical trials

21 January 2018

1 reference

Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.09.58

1 reference

21 August 2017

1 reference